With TheraTears, Prestige Consumer Sees Way To Boost Guidance Despite COVID, Cost Uncertainties

More than 17% growth in consumer health product sales in latest quarter on top of adding TheraTears brands to its lineup at start of current quarter outweighs potential headwinds from costs and changes in consumer spending, Prestige Consumer executives say.

Prestige Consumer Healthcare starts its FY2022 with higher returns in sales, net income and EPS driven by higher spending on advertising/marketing and on costs of goods sold.

Prestige Consumer Healthcare Inc. didn’t let “a lot of uncertainty” about supply chain costs and consumer spending linked to COVID-19 stop it from increasing its earnings guidance.

More than 17% growth in its OTC drug and other consumer health product sales in its latest quarter on top...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from International

More from Geography